Yahoo Finance

OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Sub-Retinal Fibrosis and Wet Macular ...

SUWON, Republic of Korea and LONDON, June 16, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (226950.KQ), a leading developer of RNAi therapeutics, today announced that the Company signed an ...
Yahoo Finance

OliX Pharmaceuticals to Present at 2021 ICR Conference

SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will ...
Investing

OliX Pharmaceuticals Inc (226950)

OliX Pharmaceuticals Inc stock price live, this page displays KQ 226950 stock exchange data. View the 226950 premarket stock price ahead of the market session or assess the after hours quote. Monitor ...
Business Wire

OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia

SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that it has received approval from the Human Research Ethics ...
Mena FN

OliX Pharmaceuticals to Conduct One-on-One Meetings with

SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company's management will ...
Business Wire

OliX Pharmaceuticals Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics

SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company identified effective inhibition of target ...
PharmiWeb

OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital·BioHealth Business Forum

OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Korea Health Industry Development Institute. The Company signed an ...
Investing

OliX Pharmaceuticals (KQ:226950) Annual Report

Aaa Aaaaaa 1,580.0 +26.34% 1,996.2 ...
WBOC

OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued ...
BioWorld

Items Tagged with 'Olix Pharmaceuticals Inc.'

The year 2025 proved especially active with regard to deals that centered on the indication previously known as nonalcoholic steatohepatitis (NASH). Dealmaking in the Asia Pacific (APAC) region took ...
Yahoo Finance

OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund

SEOUL, South Korea, June 04, 2026--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 ...